Canada Gazette, Part I, Volume 153, Number 13: GOVERNMENT NOTICES

March 30, 2019

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Ministerial Condition No. 19882

Ministerial condition

(Paragraph 84(1)(a) of the Canadian Environmental Protection Act, 1999)

Whereas the Minister of the Environment and the Minister of Health (the ministers) have assessed information pertaining to the substance iron(1+), chloro[dimethyl 9,9dihydroxy-3-methyl-2,4-di(2-pyridinyl-κN)-7-[(2-pyridinylκN)methyl]- 3,7-diazabicyclo[3.3.1]nonane-1,5-dicarboxylateκN3, κN7]-, chloride (1:1), Chemical Abstracts Service Registry No. 478945-46-9;

And whereas the ministers suspect that the substance is toxic or capable of becoming toxic within the meaning of section 64 of the Canadian Environmental Protection Act, 1999 (the Act),

The Minister of the Environment, pursuant to paragraph 84(1)(a) of the  Act, hereby permits the manufacture or import of the substance in accordance with the conditions of the following annex.

Nancy Hamzawi
Assistant Deputy Minister
Science and Technology Branch

On behalf of the Minister of the Environment

ANNEX

Conditions

(Paragraph 84(1)(a) of the Canadian Environmental Protection Act, 1999)

1. The following definitions apply in these ministerial conditions:

2. The notifier may manufacture or import the substance in accordance with the present ministerial conditions.

Restrictions

3. The substance shall only be used to manufacture a paint or a coating and the following conditions must be met:

4. The notifier shall transfer the physical possession or control of the substance only to a person who will use it in accordance with item 3.

5. At least 120 days prior to beginning manufacturing the substance in Canada, the notifier shall inform the Minister of the Environment, in writing, and provide the following information:

Record-keeping requirements

6. (1) The notifier shall maintain electronic or paper records, with any documentation supporting the validity of the information contained in these records, indicating

(2) The notifier shall maintain electronic or paper records mentioned in subsection (1) at their principal place of business in Canada, or at the principal place of business in Canada of their representative, for a period of at least five years after they are made.

Other requirements

7. The notifier shall inform any person to whom they transfer the physical possession or control of the substance, in writing, of the terms of the present ministerial conditions. The notifier shall obtain, prior to the first transfer of the substance, written confirmation from this person that they were informed of the terms of the present ministerial conditions. This written confirmation shall be maintained at the principal place of business in Canada of the notifier or of their representative in Canada for a period of at least five years from the day it was received.

Coming into force

8. The present ministerial conditions come into force on March 13, 2019.

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Notice of waiver of information requirements for living organisms (subsection 106(9) of the Canadian Environmental Protection Act, 1999)

Whereas any person who proposes to import or manufacture a living organism that is not on the Domestic Substances List must provide to the Minister of the Environment the information required under subsection 106(1) of the Canadian Environmental Protection Act, 1999;

Whereas a person may, pursuant to subsection 106(8) of the Canadian Environmental Protection Act, 1999, request any of the requirements to provide information under subsection 106(1) of the Canadian Environmental Protection Act, 1999 to be waived;

Whereas a waiver may be granted by the Minister of the Environment under subsection 106(8) of the Canadian Environmental Protection Act, 1999 if

Therefore, notice is hereby given, pursuant to subsection 106(9) of the Canadian Environmental Protection Act, 1999, that the Minister of the Environment waived some requirements to provide information in accordance with the following annex pursuant to subsection 106(8) of that Act.

Nicole Davidson
Acting Executive Director
Program Development and Engagement Division

On behalf of the Minister of the Environment

ANNEX

Notice of waiver of information requirements
(Subsection 106(9) of the Canadian Environmental Protection Act, 1999)
Person to whom a waiver was granted Information concerning a living organism in relation to which a waiver was granted
AquaBounty Technologies Inc. Data from a test to determine the ecological effects of the living organism (pathogenicity, toxicity or invasiveness)
GlaxoSmithKline Inc.

Data from a test to determine the effects of the living organism on aquatic plant, invertebrate, and vertebrate species likely to be exposed

Data from a test to determine the effects of the living organism on terrestrial plant and invertebrate species likely to be exposed

Data from tests of antibiotic susceptibility
Iovance Biotherapeutics, Inc.

Data from a test to determine the effects of the living organism on aquatic plant, invertebrate, and vertebrate species likely to be exposed

Data from a test to determine the effects of the living organism on terrestrial plant and invertebrate species likely to be exposed

Data from tests of antibiotic susceptibility

EXPLANATORY NOTE

The decision to grant a waiver is made on a case-by-case basis by Environment Canada in consultation with Health Canada. Every year an average of 500 regulatory declarations are submitted for chemicals, polymers and living organisms under subsections 81(1), (3) and (4) and 106(1), (3) and (4) of the Canadian Environmental Protection Act, 1999 and around 100 waivers are granted yearly for chemicals, polymers and living organisms under subsections 81(8) and 106(8) of the Canadian Environmental Protection Act, 1999.

For more information, please see the waivers web page on the New Substances website.

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Notice of waiver of information requirements for substances (subsection 81(9) of the Canadian Environmental Protection Act, 1999)

Whereas any person who proposes to import or manufacture a substance that is not on the Domestic Substances List must provide to the Minister of the Environment the information required under subsection 81(1) of the Canadian Environmental Protection Act, 1999;

Whereas a person may, pursuant to subsection 81(8) of the Canadian Environmental Protection Act, 1999, request any of the requirements to provide information under subsection 81(1) of the Canadian Environmental Protection Act, 1999 to be waived; and

Whereas a waiver may be granted by the Minister of the Environment under subsection 81(8) of the Canadian Environmental Protection Act, 1999 if

Therefore, notice is hereby given, pursuant to subsection 81(9) of the Canadian Environmental Protection Act, 1999, that the Minister of the Environment waived some requirements to provide information pursuant to subsection 81(8) of that Act and in accordance with the following annex.

Nicole Davidson
Acting Executive Director
Program Development and Engagement Division

On behalf of the Minister of the Environment

ANNEX

Notice of waiver of information requirements
(Subsection 81(9) of the Canadian Environmental Protection Act, 1999)
Person to whom a waiver was granted Information concerning a substance in relation to which a waiver was granted
BASF Canada Inc.

Data in respect of octanol/water partition coefficient

Data in respect of hydrolysis rate as a function of pH
Dow Chemical Canada ULC Data from an in vivo mammalian test for chromosomal aberrations or gene mutations
H.B. Fuller Canada

Data in respect of octanol/water partition coefficient (2) table 1 note 1

Data in respect of hydrolysis rate as a function of pH (2)
INEOS Oligomers USA LLC Data in respect of hydrolysis rate as a function of pH
Rohm and Haas Canada LP Data in respect of octanol/water partition coefficient
Showa Denko K.K.

Data in respect of water solubility

Data from an acute mammalian toxicity test (oral, dermal or inhalation)

Data from an in vitro mutagenicity test for chromosomal aberrations in mammalian cells
Solenis Canada ULC

Data in respect of octanol/water partition coefficient

Data in respect of hydrolysis rate as a function of pH
W.R. Grace & Co.-Conn.

Data in respect of vapour pressure

Data in respect of octanol/water partition coefficient

Data in respect of ready biodegradation

Data in respect of adsorption-desorption

Table 1 Note

Table 1 Note 1

The number in brackets indicates the number of times that the information requirement in the second column was waived for the company.

Return to table 1 note 1 referrer

EXPLANATORY NOTE

The decision to grant a waiver is made on a case-by-case basis by Environment Canada in consultation with Health Canada. Every year an average of 500 regulatory declarations are submitted for chemicals, polymers and living organisms under subsections 81(1), (3) and (4) and 106(1), (3) and (4) of the Canadian Environmental Protection Act, 1999 and around 100 waivers are granted yearly for chemicals, polymers and living organisms under subsections 81(8) and 106(8) of the Canadian Environmental Protection Act, 1999.

For more information, please see the waivers web page on the New Substances website.

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Notice with respect to the availability of an equivalency agreement

Pursuant to subsection 10(4) of the Canadian Environmental Protection Act, 1999, notice is hereby given that the Minister of the Environment makes available, before it is entered into, An Agreement on the Equivalency of Federal and British Columbia Regulations Respecting the Release of Methane from the Upstream Oil and Gas Sector in British Columbia, 2020.

The proposed agreement is available as of March 30, 2019, on the Department of the Environment’s Environmental Registry.

Any person may, within 60 days after the publication of this notice, file with the Minister comments or a notice of objection. All such comments and notices must cite the present notice and its date of publication in the Canada Gazette, Part I, and be sent to the following contact person.

Contact

Cam Carruthers
Executive Director
Oil, Gas and Alternative Energy Division
Department of the Environment
351 Saint-Joseph Boulevard
Gatineau, Quebec
K1A 0H3
Email: ec.methane-methane.ec@canada.ca

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Notice with respect to the availability of an equivalency agreement

Pursuant to subsection 10(4) of the Canadian Environmental Protection Act, 1999, notice is hereby given that the Minister of the Environment makes available, before it is entered into, the Agreement on the equivalency of federal and Nova Scotia regulations for the control of greenhouse gas emissions from electricity producers in Nova Scotia.

The proposed agreement is available as of March 30, 2019, on the Department of the Environment’s Environmental Registry.

Any person may, within 60 days after the publication of this notice, file with the Minister comments or a notice of objection. All such comments and notices must cite the present notice and its date of publication in the Canada Gazette, Part I, and be sent to the following contact person.

Contact

Magda Little
Director
Electricity and Combustion Division
Department of the Environment
351 Saint-Joseph Boulevard
Gatineau, Quebec
K1A 0H3
Email: ec.electricite-electricity.ec@canada.ca

DEPARTMENT OF THE ENVIRONMENT

Significant New Activity Notice No. 19794

Significant New Activity Notice

(Section 85 of the Canadian Environmental Protection Act, 1999)

Whereas the Minister of the Environment and the Minister of Health have assessed information in their possession in respect of the substance 2-Propenoic acid, 2-methyl-, methyl ester, polymer with isooctyl 2- propenoate and 3-[3,3,3-trimethyl-1,1-bis[(trimethylsilyl)oxy]-1-disiloxanyl]propyl 2-methyl-2-propenoate, Chemical Abstracts Service Registry No. 175283-06-4, under section 83 of the Canadian Environmental Protection Act, 1999;

Whereas the substance is not specified on the Domestic Substances List;

And whereas the Ministers suspect that a significant new activity in relation to the substance may result in the substance becoming toxic within the meaning of section 64 of the Act,

Therefore, the Minister of the Environment indicates, pursuant to section 85 of the Canadian Environmental Protection Act, 1999, that subsection 81(4) of that Act applies with respect to the substance in accordance with the Annex.

March 11, 2019

The Honourable Catherine McKenna
Minister of the Environment

ANNEX

Information requirements

(Section 85 of the Canadian Environmental Protection Act, 1999)

1. The following definition applies in this notice:

2. In relation to the substance, a significant new activity is

3. Despite section 2, a use of the substance is not a significant new activity if the substance is used

4. For each proposed significant new activity, the following information must be provided to the Minister of the Environment at least 90 days before the day on which the activity begins:

5. The information provided under section 4 will be assessed within 90 days after the day on which it is received by the Minister of the Environment.

Transitional provisions

6. Despite section 2, in the period between the date of publication of the present notice and March 30, 2020, a significant new activity is the use of the substance in a quantity greater than or equal to 1 000 kg in a calendar year in the manufacture or distribution for sale of the following products in which the substance is present in a concentration greater than or equal to 1% by weight:

7. For greater certainty, in respect of calendar year 2020, the quantity of substance that is used before March 30 of that calendar year is not considered for the purposes of section 2.

EXPLANATORY NOTE

(This explanatory note is not part of the Significant New Activity Notice.)

Description

This Significant New Activity (SNAc) Notice is a legal instrument adopted by the Minister of the Environment pursuant to section 85 of the Canadian Environmental Protection Act, 1999 (the Act) to apply the SNAc provisions of that Act to 2-Propenoic acid, 2-methyl-, methyl ester, polymer with isooctyl 2-propenoate and 3-[3,3,3- trimethyl-1,1-bis[(trimethylsilyl)oxy]-1-disiloxanyl]propyl 2-methyl-2-propenoate, Chemical Abstracts Service Registry No. 175283-06-4. The Notice is now in force. It is therefore mandatory to meet all the requirements of the Notice should a person intend to use the substance for a significant new activity as defined in the Notice.

A SNAc Notice does not constitute an endorsement from the Department of the Environment or the Government of Canada of the substance to which it relates, or an exemption from any other laws or regulations that are in force in Canada and that may apply to this substance or activities involving the substance.

Applicability of the Significant New Activity Notice

The Notice requires that any person (individual or corporation) engaging in a SNAc in relation to 2-Propenoic acid, 2-methyl-, methyl ester, polymer with isooctyl 2- propenoate and 3-[3,3,3-trimethyl-1,1-bis[(trimethylsilyl)oxy]-1-disiloxanyl]propyl 2-methyl-2-propenoate, Chemical Abstracts Service Registry No. 175283-06-4, submit a Significant New Activity Notification (SNAN) containing all of the information prescribed in the Notice at least 90 days prior to using the substance for the SNAc.

In order to address the human toxicity concerns, the Notice requires notification in relation to the use of the substance in the manufacture of consumer products or cosmetics intended for applications that generate airborne particles of less than or equal to 10 µm when the concentration of the substance is greater or equal to 1% by weight. The Notice also requires notification in relation to the distribution for sale of the substance in these finished products. For example, notification is required if a person plans to manufacture or distribute an aerosol cosmetic product containing the substance that generates respirable airborne particles of less than or equal to 10 µm, and the concentration of the substance is greater or equal to 1% by weight.

The Notice targets any use of the substance in consumer products to which the Canada Consumer Product Safety Act (CCPSA) applies, or in a cosmetic as defined in the Food and Drugs Act (FDA). A SNAN is required 90 days before the use of the substance in a SNAc.

Activities not subject to the Notice

The following activities are not significant new activities:

Uses of the substance that are regulated under the acts of Parliament listed in Schedule 2 of the Act, including the Pest Control Products Act, the Fertilizers Act and the Feeds Act, are excluded from the Notice. The Notice also does not apply to transient reaction intermediates, impurities, contaminants, partially unreacted materials or, in some circumstances, to items such as, but not limited to, wastes, mixtures, or manufactured items. However, it should be noted that individual components of a mixture may be subject to notification under the provisions of the Act. See subsection 81(6) and section 3 of the Act, and section 3 of the Guidelines for the Notification and Testing of New Substances: Chemicals and Polymers for additional information.

Activities involving the use of the substance as a research and development substance or a site-limited intermediate or an export-only product are excluded from the Notice. The terms “research and development substance” and “site-limited intermediate substance” are defined in subsection 1(1) of the New Substances Notification Regulations (Chemicals and Polymers).

Information to be submitted

The Notice sets out the information that must be provided to the Minister 90 days before the day on which the substance 2-Propenoic acid, 2-methyl-, methyl ester, polymer with isooctyl 2-propenoate and 3-[3,3,3- trimethyl-1,1-bis[(trimethylsilyl)oxy]-1-disiloxanyl]propyl 2-methyl-2-propenoate, Chemical Abstracts Service Registry No. 175283-06-4, is used for a SNAc. The Department of the Environment and the Department of Health will use the information submitted in the SNAN to conduct risk assessments within 90 days after the complete information is received.

The earlier assessment of the substance identified potential concerns associated with uses of the substance in consumer spray applications that generate respirable airborne particles of less than or equal to 10 µm. This acrylate silicone copolymer with high molecular weight and water-insoluble components can potentially cause pulmonary complications if inhaled. The SNAc Notice is issued to gather toxicity information in the event that the substance is used in a consumer spray application that generates airborne particles of less than or equal to 10 µm to ensure that the substance will undergo further assessment before SNAcs are undertaken.

The information requirements in the Notice relate to general information in respect of the substance, details surrounding its use, exposure information, and toxicity to human health. Some of the information requirements reference the New Substances Notification Regulations (Chemicals and Polymers).

Additional guidance on preparing a SNAN can be found in section 1.3 of the Guidelines for the Notification and Testing of New Substances: Chemicals and Polymers.

Transitional provision

A transitional provision is included in the Notice to facilitate compliance by persons who may already have imported or manufactured up to 1 000 kg of the substance and started activities with it in concentrations that are greater than or equal to 1% by weight in the product matrix. The Notice comes into force immediately. However, if the substance is used to manufacture or distribute for sale consumer products to which the CCPSA applies or cosmetics as defined in the FDA that release or spray the substance in airborne particles of less than or equal to 10 µm in size, a threshold of more than or equal to 1 000 kg per calendar year applies and a concentration equal to or greater than 1% by weight applies for the period between the publication of the Notice and March 30, 2020. On March 31, 2020, the threshold will be lowered to 0 kg per calendar year when the substance is used to manufacture consumer or cosmetic products that release or spray the substance in airborne particles of less than 10 µm in size, and the concentration will remain greater than or equal to 1% by weight. On March 31, 2020, the threshold will be lowered to 10 kg per calendar year when consumer or cosmetic products that release or spray the substance in airborne particles of less than or equal to 10 µm in size are intended for distribution for sale, and the concentration will remain greater than or equal to 1% by weight.

Compliance

When assessing whether or not a substance is subject to SNAc provisions, a person is expected to make use of information in their possession or to which they may reasonably have access. This means information in any of the notifier’s offices worldwide or other locations where the notifier can reasonably have access to the information. For example, manufacturers are expected to have access to their formulations, while importers or users of a substance, mixture, or product are expected to have access to import records, usage information and the relevant safety data sheets (SDSs).

Although an SDS is an important source of information on the composition of a product, it should be noted that the goal of the SDS is to protect the health of workers in the workplace from specific hazards of chemical products. Therefore, an SDS may not list all product ingredients that may be subject to a SNAc notice due to human health or environmental concerns. Any person requiring more detailed information on product composition is encouraged to contact their supplier.

If any information becomes available that reasonably supports the conclusion that 2-Propenoic acid, 2-methyl-, methyl ester, polymer with isooctyl 2-propenoate and 3-[3,3,3-trimethyl-1,1-bis[(trimethylsilyl)oxy]-1-disiloxanyl] propyl 2-methyl-2-propenoate, Chemical Abstracts Service Registry No. 175283-06-4, is toxic or capable of becoming toxic, the person who is in possession of or that has knowledge of the information and is involved in activities with the substance is obligated, under section 70 of the Act, to provide that information to the Minister without delay.

A company can submit a SNAN on behalf of its clients. For example, in cases where a person takes possession or control of a substance from another person, they may not be required to submit a SNAN, under certain conditions, if their activities were covered by an original SNAN submitted by the person from whom they obtained the substance. The Substances Management Advisory Note “Clarification in relation to the submission of Significant New Activity Notifications in application of the Canadian Environmental Protection Act, 1999” provides more detail on this subject.

Under section 86 of the Act, any person who transfers the physical possession or control of a substance subject to a SNAc notice must notify all persons to whom the physical possession or control is transferred of the obligation to comply with the notice, including the obligation to notify the Minister of any SNAc and to provide all the required information outlined above.

A pre-notification consultation (PNC) is recommended for notifiers who wish to consult with the program during the planning or preparation of their SNAN to discuss any questions or concerns they have about the prescribed information and test plans.

Where a person has questions concerning their obligations to comply with a notice, believes they may be out of compliance, or would like to request a PNC, they are encouraged to discuss their particular circumstances with the program by contacting the Substances Management Information Line (eccc.substances.eccc@canada.ca [email], 1-800‑567‑1999 [toll-free in Canada], and 819‑938‑3232 [outside of Canada]).

The Act is enforced in accordance with the publicly available Compliance and Enforcement Policy for the Canadian Environmental Protection Act, 1999. In instances of non-compliance, consideration is given to factors such as the nature of the alleged violation, potential harm, intent, and history of compliance.

DEPARTMENT OF HEALTH

CANNABIS ACT

Increase of fees

The Cannabis Fees Order (SOR/2018-198) was published in the Canada Gazette, Part II, on October 17, 2018, and came into force on the same date.

Section 2 of the Order provides that “the fees set out in sections 3 to 5 are to be adjusted in each fiscal year on April 1 by the percentage change over 12 months in the April All-items Consumer Price Index for Canada, as published by Statistics Canada under the Statistics Act, for the previous fiscal year and rounded to the next highest dollar.”

Notice is hereby given that the following fees will be adjusted effective April 1, 2019, by the 2018 Consumer Price Index of 2.2%.

Fee Description Current Fee Adjusted Fee Effective
April 1, 2019
Screening of a licence application
  • Licence for micro-cultivation
 $1,638 $1,675
  • Licence for standard cultivation
 $3,277 $3,350
  • Licence for a nursery
 $1,638 $1,675
  • Licence for micro-processing
 $1,638 $1,675
  • Licence for standard processing
 $3,277 $3,350
  • Licence for sale for medical purposes
 $3,277 $3,350
Application for security clearance $1,654 $1,691
Application for import or export permit $610 $624

John Clare
Acting Director General
Strategic Policy Directorate
Controlled Substances and Cannabis Branch

DEPARTMENT OF HEALTH

DEPARTMENT OF HEALTH ACT

Notice of annual increase of Health Canada’s Drug Master Files and Certificate of a Pharmaceutical Product fees

Notice is hereby given that the Minister of Health, under the Ministerial Authority to Enter into Contract, hereby updates the fees that are payable for the provision of Drug Master Files and Certificate of a Pharmaceutical Product services by 2%, beginning April 1, 2019.

The current fees and the fees updated as of April 1, 2019, are listed below.

Any inquiries or comments about the updated fees can be directed to Etienne Ouimette, Director General, Resource Management Operations Directorate, Health Products and Food Branch, 613‑957‑6690 (telephone) or hc.cro- brc.sc@canada.ca (email).

Services Fee as of April 1, 2018 Fee as of April 1, 2019
Certificate of Pharmaceutical Product (or a supplemental copy of a Certificate of Pharmaceutical Product) $88 $90
New Master Files —  file registration $1,224 $1,248
Drug Master Files —  letter of access $173 $176
Drug Master Files —  update $530 $541

DEPARTMENT OF HEALTH

FINANCIAL ADMINISTRATION ACT

Notice of annual increase of fees pursuant to the Fees in Respect of Drugs and Medical Devices Regulations

Notice is hereby given, under section 19.2 of the Financial Administration Act, that in keeping with section 4 of the 2011 Fees in Respect of Drugs and Medical Devices Regulations, every fee outlined by the Regulations is to be increased annually by 2%, rounded up to the nearest dollar.

The current fees and the fees updated as of April 1, 2019, are listed below.

Any inquiries or comments about the updated fees can be directed to Etienne Ouimette, Director General, Resource Management Operations Directorate, Health Products and Food Branch, 613‑957‑6690 (telephone) or hc.cro-brc.sc@canada.ca (email).

Fee Category Section in Fees in Respect of Drugs and Medical Devices Regulations Fee as of April 1, 2018 Fee as of April 1, 2019

PART 2 — DRUGS

Fees For Examination Services — Schedule 1
New active substance 6 $348,606 $355,579
Clinical or non-clinical data and chemistry and manufacturing data 6 $176,569 $180,101
Clinical or non-clinical data only 6 $82,410 $84,059
Comparative studies 6 $49,811 $50,808
Chemistry and manufacturing data only 6 $23,551 $24,023
Published data only 6 $19,530 $19,921
Switch from prescription to non-prescription status 6 $47,421 $48,370
Labelling only 6 $3,174 $3,238
Administrative submission 6 $331 $338
Disinfectants 6 $4,392 $4,480
Drug identification number application — labelling standards 6 $1,761 $1,797
Remission
Remission processing fee 11(1)(a)9)iii) $578 $590
Establishment Licence Fees Fabrication of Drugs — Schedule 2
Basic fee 19(1), 27, 28(1)(a), 28(2)(a) $17,751 $18,107
Each additional category 19(1)(a) $4,449 $4,538
Dosage form classes:    
2 classes 19(1)(b) $8,883 $9,061
3 classes 19(1)(b) $17,751 $18,107
4 classes 19(1)(b) $22,198 $22,642
5 classes 19(1)(b) $26,629 $27,162
6 classes 19(1)(b) $31,064 $31,686
Each additional class 19(1)(b) $1,783 $1,819
Sterile dosage forms 19(1)(c) $8,883 $9,061
Packaging/Labelling of Drugs — Schedule 3
Basic fee 20(1), 20(3)(a), 28(1)(b), 28(2)(b) $11,869 $12,107
Each additional category 20(1)(a) $2,966 $3,026
Dosage form classes:    
2 classes 20(1)(b) $5,920 $6,039
3 or more classes 20(1)(b) $8,883 $9,061
Importation and Distribution of Drugs — Schedule 4
Basic fee 21(a), 22, 28(1)(c) and (d), 28(2)(c) and (d) $7,402 $7,551
Each additional category 21(a)(i), 22(a) $1,853 $1,891
Dosage form classes:    
2 classes 21(a)(ii), 22(b) $3,703 $3,778
3 or more classes 21(a)(ii), 22(b) $7,402 $7,551
Each fabricator 21(b)(i) $1,783 $1,819
Each additional dosage form class for each fabricator 21(b)(ii) $899 $917
Distribution or Wholesaling
Distribution or wholesaling fee 23 $4,449 $4,538
Testing
Testing fee 24 $2,966 $3,026
Drug Analysis — Schedule 5
Vaccines (1) 25 $29,582 $30,174
Drugs, not included in items 1, 6 and 9 of this Schedule, that are listed in Schedule D to the Food and Drugs Act 25 $11,836 $12,073
Drugs for human use that are listed in Schedule F to the Food and Drug Regulations or that are controlled drugs or narcotics 25 $8,883 $9,061
Drugs for human use, not included in any other item, for which a drug identification number has been assigned 25 $4,449 $4,538
Radiopharmaceuticals 25 $0 $0
Whole blood and its components (6) 25 $0 $0
Hemodialysis products 25 $0 $0
Drugs that are labelled as disinfectants, including those listed in paragraph 9(f) of this Schedule, but excluding other drugs labelled as disinfectants of medical devices 25 $0 $0
Drugs that meet the requirements of a class monograph having one of the following titles (9): $0 $0
Acne Therapies 25 $0 $0
Antidandruff Products 25 $0 $0
Antiperspirants 25 $0 $0
Antiseptic Skin Cleaners 25 $0 $0
Athlete’s Foot Treatments 25 $0 $0
Contact Lens Disinfectants 9(f) 25 $0 $0
Fluoride-Containing Anti-Caries Products 25 $0 $0
Medicated Skin Care Products 25 $0 $0
Sunburn Protectants 25 $0 $0
Throat Lozenges 25 $0 $0

Fees for the Examination of Dealer’s Licence Applications

Dealer’s Licence
Dealer’s licence 31(1) $5,184 $5,288
Fees for Right to Sell Drugs
Annual fee 35(1) $1,176 $1,200

PART 3 — MEDICAL DEVICE FEES

Fees for the Examination of Medical Device Licence Applications

Class II Medical Devices
Class II — Licence application 39(1) $405 $414
Class III Medical Devices — Schedule 6
Licence application 40(1)(a), 41(a) $5,805 $5,922
Licence application for a near patient in vitro diagnostic devices 40(1)(a), 41(a) $9,881 $10,079
Change referred to in paragraph 34(a) of the Medical Devices Regulations that relates to manufacturing 40(1)(a), 41(a) $1,462 $1,492
Any other change referred to in paragraph 34(a) or (b) of the Medical Devices Regulations 40(1)(a), 41(a) $5,437 $5,546
Class IV Medical Devices — Schedule 7
Licence application 40(1)(b), 41(b) $13,500 $13,770
Licence application for devices that contain human or animal tissue 40(1)(b), 41(b) $12,594 $12,846
Licence application for near patient in vitro diagnostic device 40(1)(b), 41(b) $23,012 $23,473
Change referred to in paragraph 34(a) of the Medical Devices Regulations that relates to manufacturing 40(1)(b), 41(b) $1,462 $1,492
Any other change referred to in paragraph 34(a) or (b) of the Medical Devices Regulations 40(1)(b), 41(b) $6,195 $6,319
Remission
Remission processing fee 44(1)(a)(iii) $63 $65
Fee for Right to Sell Licensed Class II, III or IV Medical Devices
Fee (if annual gross revenue medical device sales is less than $20,000) 48(1)(a) $63 $65
Fee (in any other case) 48(1)(b) $383 $391
Establishment Licence Fees
Medical devices establishment licence 51(1) $8,272 $8,438

DEPARTMENT OF HEALTH

FINANCIAL ADMINISTRATION ACT

Notice of annual increase of Health Canada’s veterinary drug fees

Notice is hereby given, under section 17.1 of the Service Fees Act (a fee is adjusted in each fiscal year, on the anniversary of a date that is selected by the responsible authority with respect to the fee before the first adjustment, by the percentage change over 12 months in the April All-items Consumer Price Index for Canada, as published by Statistics Canada under the Statistics Act, for the previous fiscal year), that every fee outlined in the Veterinary Drug Evaluation Fees Regulations, the Establishment Licensing Fees (Veterinary Drugs) Regulations, the Licensed Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations, and the Authority to Sell Veterinary Drugs Fees Regulations is to be increased by 2.2%. Health Canada has chosen April 1 as the anniversary date.

The current fees and the fees updated as of April 1, 2019, are listed below.

Any inquiries or comments about the updated fees can be directed to Etienne Ouimette, Director General, Resource Management Operations Directorate, Health Products and Food Branch, 613‑957‑6690 (telephone) or hc.cro-brc.sc@canada.ca (email).

Fee Category Fees as of April 1, 2018 Fees as of April 1, 2019
Veterinary Drug Evaluation Fees
Item New drug submission
1 Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species. (In the case of an antiparasitic drug, several indications in one food animal species). $15,980.00 $16,331.56
2 Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species. $9,680.00 $9,892.96
3 Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration, dosage form and two indications in one animal species. $23,240.00 $23,751.28
4 Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species. $31,470.00 $32,162.34
5 Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration. $2,900.00 $2,963.80
6 Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength. $480.00 $490.56
7 For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species. $21,790.00 $22,269.38
8 For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species. $29,050.00 $29,689.10
9 For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration. $2,900.00 $2,963.80
10 For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species. $14,520.00 $14,839.44
11 Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug. $4,840.00 $4,946.48
12 Chemistry and manufacturing data to support one strength of a single dosage form. $4,840.00 $4,946.48
13 Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as item 12. $2,420.00 $2,473.24
14 Documentation to support a change of manufacturer. $250.00 $255.50
Supplement to a new drug submission
1 Efficacy data to support an additional indication in one animal species. $12,590.00 $12,866.98
2 Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species. $9,680.00 $9,892.96
3 Efficacy and safety data (in the intended species) to support an indication in another animal species. $15,980.00 $16,331.56
4 Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species. $23,240.00 $23,751.28
5 Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species. $31,470.00 $32,162.34
6 Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species. $7,740.00 $7,910.28
7 Comparative (pharmacodynamics, clinical or bioavailability) data to support an additional route of administration. $2,900.00 $2,963.80
8 Comparative (pharmacodynamics, clinical or bioavailability) data to support each additional strength. $480.00 $490.56
9 For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species. $2,900.00 $2,963.80
10 For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species. $14,520.00 $14,839.44
11 For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, maximum residue limit and withdrawal period. $7,260.00 $7,419.72
12 For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required. $5,810.00 $5,937.82
13 Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process. $4,840.00 $4,946.48
14 Chemistry and manufacturing data to support a change in formulation or dosage form. $2,420.00 $2,473.24
15 Chemistry and manufacturing data to support a change in packaging or in the sterilization process. $1,930.00 $1,972.46
16 Chemistry and manufacturing data to support an extension of the expiry dating. $1,450.00 $1,481.90
17 Chemistry and manufacturing data to support the concurrent use of two drugs. $1,450.00 $1,481.90
18 Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage forms. $480.00 $490.56
19 Documentation to support a change to the name of a manufacturer or the brand name of a drug. $250.00 $255.50
Abbreviated new drug submission and supplement to an abbreviated new drug submission
1 Comparative (pharmacodynamics, clinical or bioavailability) data to support a single route of administration and dosage form. $2,900.00 $2,963.80
2 For food-producing animals, residue depletion studies to confirm that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference product. $2,900.00 $2,963.80
3 Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug. $4,840.00 $4,946.48
4 Chemistry and manufacturing data to support a single dosage form. $4,840.00 $4,946.48

5

Documentation to support

  • (a) a change of manufacturer, in the case of an abbreviated new drug submission; or
  • (b) a change to the name of a manufacturer or the brand name of a drug, in the case of a supplement to an abbreviated new drug submission.
 $250.00 $255.50
Drug identification number application
1 Information, other than that referred to in item 2, to support an application for a number, including the submission of labelling material for a second review, if required. $720.00 $735.84
2 Published references or other data. $500.00 $511.00
3 Documentation to support a change of manufacturer, a change to the name of a manufacturer or a change to the brand name of a drug. $250.00 $255.50
Preclinical new drug submission
1 Efficacy and safety data (in the intended species) and protocol to support the conduct of clinical studies relative to a single dosage form, route of administration and indication in one species. $4,840.00 $4,946.48
2 Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated. $3,870.00 $3,955.14
3 For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species. $14,520.00 $14,839.44
4 For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species. $21,790.00 $22,269.38
5 For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1,000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species. $29,050.00 $29,689.10
6 For food-producing animals (once an acceptable daily intake with a safety factor of 1,000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species. $7,260.00 $7,419.72
7 Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient. $4,840.00 $4,946.48
8 Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient. $2,420.00 $2,473.24
Notifiable change or protocol review
1 Information and material to support an application for notifiable change. $1,300.00 $1,300.00
2 Request for review of scientific information outside of a regular drug submission (i.e. review of a proposed trial protocol). $1,300.00 $1,300.00
Experimental studies certificate
1 Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a non-food-producing animal. $960.00 $981.12
2 Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal. $480.00 $490.56
3 Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a food-producing animal. $2,900.00 $2,963.80
4 Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that for a previously authorized experimental studies certificate for a drug to be administered to a food-producing animal. $480.00 $490.56
Emergency drug sale
1 Information and material to support the sale of a drug to be used in the emergency treatment of a non-food-producing animal. $50.00 $51.10
2 Information and material to support the sale of a drug to be used in the emergency treatment of a food-producing animal. $100.00 $102.20

Veterinary Drug Establishment Licence Fees

Good Manufacturing Practices Component

A. Fabrication
Basic fee $6,000.00 $6,132.00
Each additional category $1,500.00 $1,533.00
Dosage form classes:
2 classes $3,000.00 $3,066.00
3 classes $6,000.00 $6,132.00
4 classes $7,500.00 $7,665.00
5 classes $9,000.00 $9,198.00
6 classes $10,500.00 $10,731.00
Each additional class $600.00 $613.20
Sterile dosage forms $3,000.00 $3,066.00
B. Packaging/Labelling
Basic fee $4,000.00 $4,088.00
Each additional category $1,000.00 $1,022.00
Dosage form classes:
2 classes $2,000.00 $2,044.00
3 or more classes $3,000.00 $3,066.00
C. Importation/Distribution
Basic fee $2,500.00 $2,555.00
Each additional category $625.00 $638.75
Dosage form classes:
2 classes $1,250.00 $1,277.50
3 or more classes $2,500.00 $2,555.00
Each fabricator $600.00 $613.20
Each additional dosage form class for each fabricator $300.00 $306.60
D. Distribution and Wholesaling
Distribution and wholesaling fee $1,500.00 $1,533.00
E. Testing
Testing fee $1,000.00 $1,022.00
Drug Analysis Component
Drug identification numbers for veterinary use $250.00 $255.50
Dealer’s Licence
Dealer’s licence $1,750.00 $1,788.50
Fees For Right To Sell Veterinary Drugs
Annual fee $250.00 $255.50

DEPARTMENT OF HEALTH

HAZARDOUS MATERIALS INFORMATION REVIEW ACT

Filing of claims for exemption

Pursuant to paragraph 12(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of the filing of the claims for exemption listed below.

In accordance with subsection 12(2) of the Hazardous Materials Information Review Act, affected parties, as defined, may make written representations to the screening officer with respect to the claim for exemption and the safety data sheet (SDS) or label to which it relates. Written representations must cite the appropriate registry number, state the reasons and evidence upon which the representations are based and be delivered within 30 days of the date of the publication of this notice in the Canada Gazette, Part I, to the screening officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 8th Floor (4908-B), Ottawa, Ontario K1A 0K9.

Véronique Lalonde
Chief Screening Officer

On February 11, 2015, the Hazardous Products Act (HPA) was amended, and the Controlled Products Regulations (CPR) and the Ingredient Disclosure List were repealed and replaced with the new Hazardous Products Regulations (HPR). The revised legislation (HPA/HPR) is referred to as WHMIS 2015.

The claims listed below seek an exemption from the disclosure of supplier confidential business information in respect of a hazardous product; such disclosure would otherwise be required under the provisions of the relevant legislation.

Claimant Product Identifier Subject of the Claim for Exemption Registry Number
Xypex Chemicals Corporation Xypex Concentrate C. of two ingredients C.i. and C. of three ingredients 12366
Xypex Chemicals Corporation Xypex Modified C. of two ingredients C.i. and C. of three ingredients 12367
Xypex Chemicals Corporation Xypex Patch’n Plug C. of two ingredients C.i. and C. of three ingredients 12368
BASF Canada Inc. Inoterra DWE C.i. and C. of one ingredient C.i. of one ingredient 12369
GREENSOLV Inc. (Produits Environnementaux Greensolv inc.) GREENSOLV 294WL C.i. and C. of four ingredients 12370
Fluid Energy Group Ltd. Enviro-Syn® HCR-7000FRAC C.i. and C. of one ingredient 03319747
Fluid Energy Group Ltd. Enviro-Syn® HCR-7000FRAC-WL C.i. and C. of one ingredient 03319912
Power Service Products DIESEL FUEL SUPPLEMENT + CETANE BOOST 1:400 Treatment Ratio C.i. of eight ingredients 03320727
Power Service Products DIESEL FUEL SUPPLEMENT + CETANE BOOST 1:1,000 Treatment Ratio C.i. of thirteen ingredients 03320726
Power Service Products DIESEL FUEL SUPPLEMENT + CETANE BOOST 1:1,500 Treatment Ratio C.i. of fourteen ingredients 03320725
Power Service Products DIESEL KLEEN + CETANE BOOST 1:400 Treatment Ratio C.i. of nine ingredients 03320723
Power Service Products DIESEL KLEEN + CETANE BOOST 1:1,000 Treatment Ratio C.i. of nine ingredients 03320722
Power Service Products DIESEL KLEEN + CETANE BOOST 1:1,500 Treatment Ratio C.i. of nine ingredients 03320720
ROMIX, Inc. BACK-SET MOLECULAR CEMENT DISSOLVER C.i. and C. of one ingredient 03320950
Imperial Oil Limited VALVE GREASE NO.1 C.i. and C. of one ingredient 03320737
Multi-Chem Production Chemicals Co. (C/O Multi-Chem Group LLC) RockOn™ MX 5-3447 C.i. of three ingredients 03319910
BASF Canada Inc. Irgacor L 844 C.i. and C. of one ingredient 03319808
Fluid Energy Group Ltd. Enviro-Syn® HCR-2000CEF C.i. and C. of one ingredient 03319909
BASF Canada Inc. Irgalube 875 C.i. of one ingredient 03319809
Ecolab Co. Ultrasil 09 C.i. of one ingredient 03320190
Canadian Energy Services LP ENERSCAV C C.i. and C. of one ingredient 03321522
Integrity Bio-Chem CleanSurf™ 55 C.i. and C. of one ingredient 03320815
Covestro LLC DESMODUR WP 260 C.i. and C. of one ingredient C. of one ingredient 03320730
Flotek Chemistry EZ Mulse C.i. and C. of one ingredient 03320862
Nalco Canada ULC PARA01532A C.i. and C. of one ingredient 03320238
Nalco Canada ULC MNE6200 C.i. and C. of five ingredients 03321150
Nalco Canada ULC PARA01570A C.i. and C. of one ingredient 03321198
Nalco Canada ULC DURASOFT™ 64870 C.i. of two ingredients 03321047
SUEZ Water Technologies & Solutions Canada SPEC-AID 8Q107ULS C.i. and C. of one ingredient 03321005
SUEZ Water Technologies & Solutions Canada PROSWEET S1791 C.i. and C. of one ingredient 03321485
SUEZ Water Technologies & Solutions Canada PETROFLO 20Y99 C.i. and C. of two ingredients 03321004
SUEZ Water Technologies & Solutions Canada PHILMPLUS 5K35 C.i. and C. of three ingredients 03321486
SUEZ Water Technologies & Solutions Canada STYREX40 C.i. and C. of one ingredient 03321003
SUEZ Water Technologies & Solutions Canada STYREX50 C.i. and C. of one ingredient 03321000
SUEZ Water Technologies & Solutions Canada PETROFLO 20Y98 C.i. and C. of two ingredients 03320998
Covestro LLC SOFTCEL POLYOL VE-1500 C.i. and C. of one ingredient 03321185
Covestro LLC SOFTCEL POLYOL VE-1800 C.i. and C. of one ingredient 03321184
Nalco Canada ULC ENTERFAST™ EC9008B C.i. of one ingredient 03321066
WD-40 Company (Canada) Ltd. 3-IN-ONE® RVcare Rubber Seal Conditioner C.i. of one ingredient 03321767
Nalco Canada ULC NALCO® EC1436A C.i. of two ingredients 03321073
Nalco Canada ULC Clar10650A C.i. of one ingredient 03321187
Evonik Canada Inc. Protectosil® CHEM-TRETE® PB 100 C.i. and C. of two ingredients and one toxicological study 03321312
Integrity Bio-Chem CleanSurf™ 55W C.i. of one ingredient 03321656
SUEZ Water Technologies & Solutions Canada GENGARD GN8020 C.i. and C. of one ingredient 03321738
SUEZ Water Technologies & Solutions Canada GENGARD GN8220 C.i. and C. of one ingredient 03321739
SUEZ Water Technologies & Solutions Canada GENGARD GN8221 C.i. and C. of one ingredient 03321740
SUEZ Water Technologies & Solutions Canada GENGARD GN8222 C.i. and C. of one ingredient 03321741
SUEZ Water Technologies & Solutions Canada GENGARD GN8224 C.i. and C. of one ingredient 03321742
SUEZ Water Technologies & Solutions Canada GENGARD GN8225 C.i. and C. of one ingredient 03321744
SUEZ Water Technologies & Solutions Canada GENGARD GN8240 C.i. and C. of one ingredient 03321745
SUEZ Water Technologies & Solutions Canada GENGARD GN8021 C.i. and C. of one ingredient 03321746

Note: C.i. = chemical identity and C. = concentration

DEPARTMENT OF HEALTH

PATENT ACT

Notice of annual increase of fees pursuant to the Certificate of Supplementary Protection Regulations

Notice is hereby given that, in keeping with subsection 9(1) of the Certificate of Supplementary Protection Regulations, the fee will increase by the annual 2% amount, rounded up to the nearest dollar.

The current fee and the fee updated as of April 1, 2019, are listed below.

Any inquiries or comments about the updated fees can be directed to Etienne Ouimette, Director General, Resource Management Operations Directorate, Health Products and Food Branch, 613‑957‑6690 (telephone) or hc.cro-brc.sc@canada.ca (email).

  Subsection in Certificate of Supplementary Protection Regulations Fee as of April 1, 2018 Fee as of April 1, 2019
Certificate of Supplementary Protection 9(1) $9,192 $9,376

DEPARTMENT OF TRANSPORT

CANADA TRANSPORTATION ACT

Levy on shipments of crude oil by rail

Pursuant to subsection 155.4(4) footnote * of the Canada Transportation Act (the Act), the amount of the levy in respect of payments into the Fund for Railway Accidents Involving Designated Goods required by subsection 155.7(1)footnote * of the Act is $1.76 per tonne during the year commencing April 1, 2019.

March 4, 2019

Marc Garneau, P.C., M.P.
Minister of Transport

INNOVATION, SCIENCE AND ECONOMIC DEVELOPMENT CANADA

RADIOCOMMUNICATION ACT

Notice No. SMSE-003-19 — Release of Decision on the Technical and Policy Framework for White Space Devices and Decision on the Technical, Policy and Licensing Framework for Wireless Microphones

Notice is hereby given that Innovation, Science and Economic Development Canada (ISED) has published the following decisions:

These decisions respectively address spectrum utilization by white space devices in the very high frequency and ultra-high frequency ranges, and wireless microphones in the ultra-high frequency and super high frequency ranges.

Obtaining copies

Copies of this notice and of documents referred to herein are available electronically on the Spectrum Management and Telecommunications website.

Official versions of notices can be viewed on the Canada Gazette website.

March 2019

Martin Proulx
Director General
Engineering, Planning and Standards Branch

OFFICE OF THE SUPERINTENDENT OF FINANCIAL INSTITUTIONS

BANK ACT

Silicon Valley Bank — Order to commence and carry on business in Canada

Notice is hereby given of the issuance, pursuant to subsection 534(1) of the Bank Act, of an order authorizing a foreign bank, Silicon Valley Bank, to commence and carry on business in Canada, effective February 27, 2019. The foreign bank is permitted to carry on business in Canada under the name, in English, Silicon Valley Bank and, in French, Banque Silicon Valley.

March 12, 2019

Jeremy Rudin
Superintendent of Financial Institutions

PRIVY COUNCIL OFFICE

Appointment opportunities

We know that our country is stronger — and our government more effective — when decision-makers reflect Canada’s diversity. The Government of Canada has implemented an appointment process that is transparent and merit-based, strives for gender parity, and ensures that Indigenous peoples and minority groups are properly represented in positions of leadership. We continue to search for Canadians who reflect the values that we all embrace: inclusion, honesty, fiscal prudence, and generosity of spirit. Together, we will build a government as diverse as Canada.

We are equally committed to providing a healthy workplace that supports one’s dignity, self-esteem and the ability to work to one’s full potential. With this in mind, all appointees will be expected to take steps to promote and maintain a healthy, respectful and harassment-free work environment.

The Government of Canada is currently seeking applications from diverse and talented Canadians from across the country who are interested in the following positions.

Current opportunities

The following opportunities for appointments to Governor in Council positions are currently open for applications. Every opportunity is open for a minimum of two weeks from the date of posting on the Governor in Council Appointments website.

Position Organization Closing date
Chief Administrator Administrative Tribunals Support Service of Canada  
Chairperson Asia-Pacific Foundation of Canada  
Chairperson Canada Development Investment Corporation  
Chairperson Canada Foundation for Sustainable Development Technology  
Chairperson and Vice-Chairperson Canada Industrial Relations Board  
Chairperson Canada Lands Company Limited  
President and Chief Executive Officer Canada Lands Company Limited  
Chairperson (joint federal Governor in Council and provincial Lieutenant Governor appointment) Canada–Newfoundland and Labrador Offshore Petroleum Board  
Chairperson Canada Science and Technology Museum  
Vice-Chairperson Canada Science and Technology Museum  
Board Member (Anticipatory) Canadian Accessibility Standards Development Organization  
Chairperson (Anticipatory) Canadian Accessibility Standards Development Organization  
Chief Executive Officer (Anticipatory) Canadian Accessibility Standards Development Organization  
Vice-Chairperson (Anticipatory) Canadian Accessibility Standards Development Organization  
President and Chief Executive Officer Canadian Commercial Corporation  
Chairperson Canadian Dairy Commission  
Chairperson, Vice-Chairperson and Director Canadian Energy Regulator  
Chief Executive Officer (Anticipatory) Canadian Energy Regulator  
Lead Commissioner, Deputy Lead Commissioner and Commissioner Canadian Energy Regulator  
Pay Equity Commissioner Canadian Human Rights Commission  
Chairperson Canadian Institutes of Health Research  
Vice-Chairperson Canadian Museum of Nature  
Permanent Member Canadian Nuclear Safety Commission  
Regional Member (Quebec) Canadian Radio-television and Telecommunications Commission  
Chairperson and Member Canadian Statistics Advisory Council  
President (Chief Executive Officer) Canadian Tourism Commission  
President and Chief Executive Officer Defense Construction (1951) Limited  
Chairperson Farm Credit Canada  
President and Chief Executive Officer Farm Credit Canada  
Vice-Chairperson Farm Products Council of Canada  
Chairperson The Federal Bridge Corporation Limited  
Commissioner Financial Consumer Agency of Canada  
Chairperson First Nations Financial Management Board  
Chief Commissioner First Nations Tax Commission  
Deputy Chief Commissioner First Nations Tax Commission  
Director Freshwater Fish Marketing Corporation  
Director (Federal) Hamilton Port Authority  
Sergeant-at-Arms and Corporate Security Office House of Commons  
Member International Authority  
Commissioner and Chairperson International Joint Commission  
Member (appointment to roster) International Trade and International Investment Dispute Settlement Bodies  
Vice-Chairperson Invest in Canada Hub  
Chief Executive Officer The Jacques Cartier and Champlain Bridges Incorporated  
Librarian and Archivist of Canada Library and Archives of Canada  
President and Chief Executive Officer Marine Atlantic Inc.  
Vice-Chairperson National Arts Centre Corporation  
Member National Capital Commission  
Government Film Commissioner National Film Board  
Chairperson National Research Council of Canada  
President Natural Sciences and Engineering Research Council of Canada  
Canadian Ombudsperson Office of the Canadian Ombudsperson for Responsible Enterprise  
Chief Accessibility Officer (Anticipatory) Office of the Chief Accessibility Officer  
Ombudsperson Office of the Ombudsperson for National Defence and Canadian Forces  
Director (Federal) Oshawa Port Authority  
Chairperson Pacific Pilotage Authority  
Chief Executive Officer Parks Canada  
Vice-Chairperson and Member Patented Medicine Prices Review Board  
Member Payment in Lieu of Taxes Dispute Advisory Panel  
Commissioner Public Service Commission  
Member and Alternate Member Renewable Resources Board (Gwich’in)  
Member and Alternate Member Renewable Resources Board (Sahtu)  
Chairperson and Vice-Chairperson Royal Canadian Mounted Police External Review Committee  
Principal Royal Military College of Canada  
Vice-Chairperson (all streams) Social Security Tribunal of Canada  
Chairperson Telefilm Canada  
Member (Marine and Medical) Transportation Appeal Tribunal of Canada  
President and Chief Executive Officer VIA Rail Canada Inc.  

BANK OF CANADA

Statement of financial position as at February 28, 2019
(Millions of dollars) Unaudited
ASSETS Amount Total
Cash and foreign deposits   17.8
Loans and receivables
Securities purchased under resale agreements 9,709.8  
Advances —  
Other receivables 4.0  
    9,713.8
Investments
Treasury bills of Canada 23,828.1  
Canada Mortgage Bonds 252.3  
Government of Canada bonds 79,490.0  
Other investments 431.5  
    104,001.9
Capital assets
Property and equipment 599.8
Intangible assets 46.4
Right-of-use leased assets 53.7  
    699,9
Other assets   187.7
Total assets   114,621.1
LIABILITIES AND EQUITY Amount Total
Bank notes in circulation   86,328.4
Deposits
Government of Canada 23,730.3  
Members of Payments Canada 250.4  
Other deposits 3,018.8  
    26,999.5
Securities sold under repurchase agreements   —
Other liabilities   769.7
    114,097.6
Equity
Share capital 5.0  
Statutory and special reserves 125.0  
Investment revaluation reservefootnote 1* 393.5  
    523.5
Total Liabilities and Equity 114,621.1

I declare that the foregoing statement is correct according to the books of the Bank.

Ottawa, March 15, 2019

Carmen Vierula
Chief Financial Officer and Chief Accountant

I declare that the foregoing statement is to the best of my knowledge and belief correct, and shows truly and clearly the financial position of the Bank, as required by section 29 of the Bank of Canada Act.

Ottawa, March 15, 2019

Stephen S. Poloz
Governor